MA41038A - Composés d'aminopyridyloxypyrazole - Google Patents

Composés d'aminopyridyloxypyrazole

Info

Publication number
MA41038A
MA41038A MA041038A MA41038A MA41038A MA 41038 A MA41038 A MA 41038A MA 041038 A MA041038 A MA 041038A MA 41038 A MA41038 A MA 41038A MA 41038 A MA41038 A MA 41038A
Authority
MA
Morocco
Prior art keywords
compounds
cancer
aminopyridylooxpyrazole
tgfpri
glioblastoma
Prior art date
Application number
MA041038A
Other languages
English (en)
Other versions
MA41038B1 (fr
Inventor
Douglas W Beight
David A Coates
Sajan Joseph
William T Mcmillen
Saravanan Parthasarathy
Huaxing Pei
Jason Scott Sawyer
Craig D Wolfangel
Gaiying Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA41038A publication Critical patent/MA41038A/fr
Publication of MA41038B1 publication Critical patent/MA41038B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés daminopyridylooxpyrazole qui inhibent l'activité du récepteur 1 du facteur du croissance transformant beta (tgfpri), des compositions pharmaceutiques comprenant les composés et des procédés d'utilisation des composés pour traiter le cancer du colon,mélanome carcinomehépatocellulaire, cancer rénal, glioblastome, cancer du pancréas, syndrome myélodysplasique, cancer du poumon et cancer gastrique et/ou la fibrose, de préference cirrhose du foie et maladie rénale chronique.
MA41038A 2014-10-07 2015-09-30 Composés d'aminopyridyloxypyrazole MA41038B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060724P 2014-10-07 2014-10-07
EP15777845.7A EP3204377B1 (fr) 2014-10-07 2015-09-30 Composés d'aminopyridyloxypyrazole
PCT/US2015/053098 WO2016057278A1 (fr) 2014-10-07 2015-09-30 Composés d'aminopyridyloxypyrazole

Publications (2)

Publication Number Publication Date
MA41038A true MA41038A (fr) 2017-08-16
MA41038B1 MA41038B1 (fr) 2018-10-31

Family

ID=54266692

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41038A MA41038B1 (fr) 2014-10-07 2015-09-30 Composés d'aminopyridyloxypyrazole

Country Status (42)

Country Link
US (1) US9617243B2 (fr)
EP (1) EP3204377B1 (fr)
JP (1) JP6043894B2 (fr)
KR (1) KR101921847B1 (fr)
CN (1) CN106795139B (fr)
AP (1) AP2017009836A0 (fr)
AR (1) AR102003A1 (fr)
AU (1) AU2015328553C1 (fr)
BR (1) BR112017005453B1 (fr)
CA (1) CA2961262C (fr)
CL (1) CL2017000765A1 (fr)
CO (1) CO2017002233A2 (fr)
CR (1) CR20170072A (fr)
CY (1) CY1120903T1 (fr)
DK (1) DK3204377T3 (fr)
DO (1) DOP2017000090A (fr)
EA (1) EA031830B1 (fr)
EC (1) ECSP17021097A (fr)
ES (1) ES2700376T3 (fr)
GT (1) GT201700067A (fr)
HR (1) HRP20181797T1 (fr)
IL (1) IL250543B (fr)
JO (1) JO3336B1 (fr)
LT (1) LT3204377T (fr)
MA (1) MA41038B1 (fr)
MX (1) MX367360B (fr)
MY (1) MY190541A (fr)
NZ (1) NZ729800A (fr)
PE (1) PE20170662A1 (fr)
PH (1) PH12017500635B1 (fr)
PL (1) PL3204377T3 (fr)
PT (1) PT3204377T (fr)
RS (1) RS58094B1 (fr)
SG (1) SG11201702481UA (fr)
SI (1) SI3204377T1 (fr)
SV (1) SV2017005411A (fr)
TN (1) TN2017000046A1 (fr)
TR (1) TR201816415T4 (fr)
TW (1) TWI582083B (fr)
UA (1) UA118807C2 (fr)
WO (1) WO2016057278A1 (fr)
ZA (1) ZA201701175B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089800A1 (fr) 2013-12-19 2015-06-25 Eli Lilly And Company Composés fluorophényl-pyrazole
CA2935392C (fr) 2014-01-01 2022-07-26 Medivation Technologies, Inc. Derives de pyridine aminee pour le traitement de conditions associees a une activite excessive de tgf-.beta.
WO2016066664A1 (fr) * 2014-10-31 2016-05-06 F. Hoffmann-La Roche Ag Nouveaux composés pyridinyloxy- et phényloxy-pyrazolyle
CN109831907A (zh) * 2016-09-30 2019-05-31 伊莱利利公司 2-{4-[(4-{[1-环丙基-3-四氢-2h-吡喃-4-基)-1h-吡唑-4-基]氧基}吡啶-2-基)氨基]吡啶-2-基}丙-2-醇治疗癌症的用途
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
JP2020512400A (ja) * 2017-03-23 2020-04-23 クラヴィウス ファーマシューティカルズ，エルエルシー ＴＧＦβの阻害のための三置換イミダゾールおよび治療方法
WO2019013790A1 (fr) * 2017-07-12 2019-01-17 Curza Global, Llc Composés antimicrobiens et leurs utilisations
CN107540672A (zh) * 2017-10-10 2018-01-05 牡丹江医学院 一种治疗肝硬化的药物及其合成方法
CN108912103A (zh) * 2018-01-21 2018-11-30 吕迎春 一种2-乙酸酯咪唑类化合物及其在防治骨质疏松药物中的应用
WO2019244001A1 (fr) * 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles en tant que modulateurs de roryt
CN112867724B (zh) 2018-07-23 2024-06-04 熙源安健医药(北京)有限公司 二膦酸盐药物缀合物
WO2020023910A1 (fr) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Procédés de traitement de maladies associées à l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destinés à être utilisés dans ceux-ci
WO2020041562A1 (fr) * 2018-08-22 2020-02-27 Clavius Pharmaceuticals, Llc Imidazoles substitués pour l'inhibition de tgf-bêta et méthodes de traitement
US20210395235A1 (en) * 2018-10-18 2021-12-23 Nanjing Sanhome Pharmaceutical Co., Ltd. COMPOUND AS TGF-beta R1 INHIBITOR AND APPLICATION THEREOF
WO2020088526A1 (fr) * 2018-10-31 2020-05-07 南京明德新药研发有限公司 COMPOSÉ DOUBLE PYRAZOLE TENANT LIEU D'INHIBITEUR DU RÉCEPTEUR TCF-βR1 DE LA KINASE
WO2020103817A1 (fr) * 2018-11-20 2020-05-28 南京圣和药业股份有限公司 INHIBITEUR DE TGF-βR1 ET SON UTILISATION
CA3117838A1 (fr) 2018-12-27 2020-07-02 Nexys Therapeutics, Inc. Derives de (pyridin-2-yl)amine utilises comme inhibiteurs de tgf-beta r1 (alk5) pour le traitement du cancer
JP2022517951A (ja) * 2019-01-10 2022-03-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 骨髄異形成症候群を処置するためのａｌｋ５阻害剤
KR102740196B1 (ko) 2019-01-24 2024-12-10 지앙수 아오사이캉 파마수티칼 씨오., 엘티디. TGF-β R1 키나아제 억제제로서의 5-(4-피리딜옥시)피라졸 화합물
WO2020258006A1 (fr) * 2019-06-25 2020-12-30 Inventisbio Shanghai Ltd. Composés hétérocycliques, leurs procédés de préparation et leurs méthodes d'utilisation
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途
WO2021129621A1 (fr) * 2019-12-23 2021-07-01 江苏先声药业有限公司 Composés pyrazole
CN112812105B (zh) * 2020-03-24 2025-04-01 苏州阿尔脉生物科技有限公司 一种氨基吡啶基氧基吡唑类衍生物及其制备方法和应用
CN111116565B (zh) * 2020-04-01 2020-07-14 中科利健制药(广州)有限公司 2-芳基-4-（4-吡唑氧基）吡啶类化合物、其制备方法、药物组合物与应用
CN111303135A (zh) * 2020-04-01 2020-06-19 中科利健制药(广州)有限公司 4-（4-吡唑氧基）喹啉类化合物、其制备方法、药物组合物与应用
WO2021204626A1 (fr) 2020-04-06 2021-10-14 Almirall, S.A. Composés hétéroaryle substitués par aryle et hétéroaryle-carboxamide utiles en tant qu'inhibiteurs de tyk2
CN113698395B (zh) * 2020-05-22 2023-12-08 赛诺哈勃药业（成都）有限公司 转化生长因子受体拮抗剂、其制备方法和应用
CN114867723B (zh) * 2020-07-23 2023-05-30 江苏奥赛康药业有限公司 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
AU2023239988A1 (en) * 2022-03-22 2024-10-10 Autotelic Bio Inc. Thiazole derivative compound and uses thereof
CN119330934B (zh) * 2023-07-21 2025-12-05 中国人民解放军军事科学院军事医学研究院 一种靶向Smurf1蛋白的降解剂、制备方法及用途
WO2025063820A1 (fr) * 2023-09-21 2025-03-27 오토텔릭바이오 주식회사 Composition pour le traitement de la fibrose pulmonaire comprenant un composé dérivé de thiazole
WO2025063819A1 (fr) * 2023-09-21 2025-03-27 오토텔릭바이오 주식회사 Composition pour le traitement d'une maladie fibrotique comprenant un composé dérivé de thiazole

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289116T3 (es) 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
UY31281A1 (es) * 2007-08-13 2009-03-31 Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
AU2012240240A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
TW201329067A (zh) * 2011-12-08 2013-07-16 Amgen Inc 作為ｇｋａ活化劑之脲化合物
WO2015089800A1 (fr) 2013-12-19 2015-06-25 Eli Lilly And Company Composés fluorophényl-pyrazole

Also Published As

Publication number Publication date
ECSP17021097A (es) 2018-02-28
CY1120903T1 (el) 2020-05-29
IL250543A0 (en) 2017-03-30
GT201700067A (es) 2019-10-10
MX367360B (es) 2019-08-16
BR112017005453A8 (pt) 2018-04-24
EA031830B1 (ru) 2019-02-28
DK3204377T3 (en) 2018-11-26
BR112017005453A2 (pt) 2017-12-12
KR20170045348A (ko) 2017-04-26
PE20170662A1 (es) 2017-05-26
JO3336B1 (ar) 2019-03-13
CL2017000765A1 (es) 2017-12-15
HRP20181797T1 (hr) 2018-12-28
JP2016535745A (ja) 2016-11-17
CN106795139A (zh) 2017-05-31
AP2017009836A0 (en) 2017-03-31
NZ729800A (en) 2018-07-27
PT3204377T (pt) 2018-12-19
RS58094B1 (sr) 2019-02-28
TN2017000046A1 (en) 2018-07-04
ZA201701175B (en) 2019-01-30
CN106795139B (zh) 2019-08-09
SG11201702481UA (en) 2017-04-27
CR20170072A (es) 2017-05-12
KR101921847B1 (ko) 2018-11-23
WO2016057278A1 (fr) 2016-04-14
PL3204377T3 (pl) 2019-02-28
LT3204377T (lt) 2018-12-27
IL250543B (en) 2020-06-30
US9617243B2 (en) 2017-04-11
EP3204377B1 (fr) 2018-09-26
BR112017005453B1 (pt) 2022-12-06
DOP2017000090A (es) 2017-04-30
TW201623282A (zh) 2016-07-01
MA41038B1 (fr) 2018-10-31
UA118807C2 (uk) 2019-03-11
CA2961262C (fr) 2019-10-22
EA201790476A1 (ru) 2017-08-31
PH12017500635A1 (en) 2017-09-25
JP6043894B2 (ja) 2016-12-14
EP3204377A1 (fr) 2017-08-16
SI3204377T1 (sl) 2018-11-30
CA2961262A1 (fr) 2016-04-14
AU2015328553A1 (en) 2017-03-09
US20160096823A1 (en) 2016-04-07
SV2017005411A (es) 2017-04-21
TWI582083B (zh) 2017-05-11
MY190541A (en) 2022-04-27
TR201816415T4 (tr) 2018-11-21
PH12017500635B1 (en) 2020-02-21
MX2017004457A (es) 2017-06-19
AU2015328553B2 (en) 2018-04-12
CO2017002233A2 (es) 2017-05-31
AU2015328553C1 (en) 2018-11-15
AR102003A1 (es) 2017-01-25
ES2700376T3 (es) 2019-02-15

Similar Documents

Publication Publication Date Title
MA41038A (fr) Composés d'aminopyridyloxypyrazole
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
EA201792047A1 (ru) Новые соединения
PH12021552538A1 (en) Heavy chain antibodies binding to psma
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
SG10201909796PA (en) Chemosensory receptor ligand-based therapies
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
MX382877B (es) Compuestos de tetrahidropiranilcarbonil-2,3-dihidro-1h-indol para tratar cancer.
MX379811B (es) Citocinas quimiotácticas como moduladores de los receptores ccr2 y el uso de las mismas en el tratamiento de enfermedades
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
MX2022005404A (es) Compuestos de fijación a il-2r e il-7r dual.
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
MA53765B2 (fr) Tubulysines et conjugués tubulysines-protéines
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
EP4678660A3 (fr) Anticorps contre le récepteur de l'activine de type ii pour utilisation dans le traitement de l'insuffisance cardiaque
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
HK1255438A1 (zh) 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
PH12019502717A1 (en) Recombinant robo2 proteins, compositions, methods and uses thereof
MX2022000317A (es) Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.
PL426662A1 (en) Composition for intravitreal administration of therapeutic protein
MA44558B1 (fr) Dérivé du glucagon, conjugué de celui-ci, composition le comprenant et utilisation thérapeutique de celui-ci